


Stabilis



Ondansetron hydrochloride



Noms commerciaux

Amal	Mexique
Ansentron	Brésil
Antivon	Chili, Mexique
Atossa	Pologne
Avessaron	Belgique
Axisetron	Allemagne
Bryterol	Colombie, Equateur
Cellondan	Allemagne
Chemoset	Maroc
Danac	Mexique
Danofran	Egypte
Danset	Egypte
Dantron	Afrique du sud, Maroc
Dasentron	Arabie Saoudite, Argentine
Dismolan	Argentine, Vénézuëla
Donset	Inde
Emeset	Inde, Roumanie, Turquie
Emetron	Hongrie, Pologne
Emistop	Mexique, Pérou
Indansen	Mexique
Nauseyron	Afrique du sud
Ondansan	Autriche
Ondatron	Allemagne
Setronon	Croatie
Vomiz	Afrique du sud
Yatrox	Espagne
Zofer	Turquie
Zofran	Allemagne, Arabie Saoudite, Argentine, Autriche, Belgique, Canada, Colombie, Danemark, Egypte, Emirats Arabes Unis, Equateur, Etats Unis d'Amérique, Finlande, Grande Bretagne, Hongrie, Irlande, Islande, Italie, Luxembourg, Malaisie, Maroc, Norvège, Nouvelle Zélande, Pays bas, Pérou, Pologne, Portugal, Suède, Suisse, Turquie
Zofron	Grèce
Zontron	Turquie
Zophren	France, Tunisie
Zotrix	Suède



Stabilité des solutions





























































































































PVC		0,024 & 0,096 mg/ml	21-26°C		14			333
PVC		0,024 & 0,096 mg/ml	4°C - 6°C		14			333
PVC		0,03 & 0,3 mg/ml	-20°C		90			183
PVC		0,03 & 0,3 mg/ml	25°C		48			183
PVC		0,03 & 0,3 mg/ml	4°C		14			183
PVC		0,08 mg/ml	-20°C		120			917
PVC		0,08 mg/ml	4°C		120			917
PVC		0,24 mg/ml	30°C		24			179
PVC		0,24 mg/ml	3°C		30			179
PVC		2 mg/ml	30°C		7			179
PP		0,25 & 0,5 & 1 mg/ml	-20°C		90			915
PP		0,25 & 0,5 & 1 mg/ml	22-25°C		48			915
PP		0,25 & 0,5 & 1 mg/ml	4°C		14			915
PP		2 mg/ml	-20°C		90			915
PP		2 mg/ml	22-25°C		48			915
PP		2 mg/ml	4°C		14			915
PI		0,03 & 0,3 mg/ml	4°C		14			113



Stabilité en mélange

		0,14 & 0,45 mg/ml	25°C		Dexamethasone sodium phosphate : 0,34 mg/ml	24		25
		0,015 >> 0,15 mg/ml	23°C		Piperacillin sodium / tazobactam : 20/2,5 >> 40/5 mg/ml	4		16
		0,03 & 0,3 mg/ml	23°C		Paclitaxel : 0,3 & 1,2 mg/ml	4		47
		0,3 mg/ml	23°C		Paclitaxel : 1,2 mg/ml Ranitidine hydrochloride : 2,0 mg/ml	4		47
		0,03 & 0,3 mg/ml	25°C		Ranitidine hydrochloride : 0,5 & 2 mg/ml	4		18
		0,44 mg/ml	25°C		Lorazepam : 0,028 mg/ml Dexamethasone sodium phosphate : 0,28 mg/ml	24		25
PVC		0,15 mg/ml	15-25°C		Dexamethasone sodium phosphate : 0,43 mg/ml	28		23
PVC		0,15 mg/ml	2-8°C		Dexamethasone sodium phosphate : 0,43 mg/ml	28		23

PVC		0,05 mg/ml	23°C-25°C		Cyclophosphamide : 0,3 mg/ml	4		50
PVC		0,4 mg/ml	23°C-25°C		Cyclophosphamide : 2 mg/ml	4		50
PVC		0,14 & 0,45 mg/ml	25°C		Dexamethasone sodium phosphate : 0,28 mg/ml	24		25
PVC		0,05 mg/ml	4°C		Cyclophosphamide : 0,3 mg/ml	8		50
PVC		0,4 mg/ml	4°C		Cyclophosphamide : 2 mg/ml	8		50
PVC		0,1 >> 0,4 mg/ml	2-6°C		Dexamethasone sodium phosphate : 0,02 & 0,4 mg/ml	30		30
PVC		0,1 >> 0,64 mg/ml	2-6°C		Dexamethasone sodium phosphate : 0,2 & 0,4 mg/ml	30		30
PVC		1,091 mg/ml	2-8°C		Cisplatin : 0,455 mg/ml	24		53
PVC		0,1 & 1 mg/ml	22°C		Pethidine hydrochloride : 4 mg/ml	31		332
PVC		0,1 & 1 mg/ml	22°C		Hydromorphone hydrochloride : 0,5 mg/ml	31		6
PVC		0,1 & 1 mg/ml	22°C		Morphine sulfate : 1 mg/ml	31		6
PVC		0,1 >> 0,4 mg/ml	22°C-23°C		Dexamethasone sodium phosphate : 0,2 & 0,4 mg/ml	48		30
PVC		0,1 >> 0,64 mg/ml	22°C-23°C		Dexamethasone sodium phosphate : 0,2 & 0,4 mg/ml	48		30
PVC		1,091 mg/ml	30°C		Cisplatin : 0,455 mg/ml	168		53
PVC		0,96 mg/ml	30°C		Doxorubicin hydrochloride : 0,8 mg/ml Vincristine sulfate : 0,028 mg/ml	5		26
PVC		0,1 & 1 mg/ml	32°C		Hydromorphone hydrochloride : 0,5 mg/ml	7		6
PVC		0,1 & 1 mg/ml	32°C		Pethidine hydrochloride : 4 mg/ml	7		332
PVC		0,1 & 1 mg/ml	32°C		Morphine sulfate : 1 mg/ml	7		6
PVC		0,1 & 1 mg/ml	4°C		Hydromorphone hydrochloride : 0,5 mg/ml	31		6
PVC		0,1 & 1 mg/ml	4°C		Pethidine hydrochloride : 4 mg/ml	31		332
PVC		0,1 & 1 mg/ml	4°C		Morphine sulfate : 1 mg/ml	31		6
PVC		0,1 & 1 mg/ml	4°C-22°C		Hydromorphone hydrochloride : 0,5 mg/ml	31		6
PVC		0,03 & 0,3 mg/ml	21°C-23°C		Cytarabine : 0,2 & 40 mg/ml	48		184
PVC		0,03 & 0,3 mg/ml	21°C-23°C		Doxorubicin hydrochloride : 0,1 & 2 mg/ml	48		184
PVC		0,03 & 0,3 mg/ml	21°C-23°C		Etoposide : 0,1 & 0,4 mg/ml	48		184
PVC		0,03 & 0,3 mg/ml	21°C-23°C		Methotrexate sodium : 0,5 & 6 mg/ml	48		184
PVC		0,64 mg/ml	30°C		Dacarbazine : 8 mg/ml Doxorubicin hydrochloride : 0,8 mg/ml	24		26
PVC		0,64 mg/ml	4°C		Dacarbazine : 8 mg/ml Doxorubicin hydrochloride : 0,8 mg/ml	7		26
PE		0,09 mg/ml	- 20°C		Dexamethasone sodium phosphate : 0,09 mg/ml	90		3174
PE		0,09 mg/ml	2-8°C		Dexamethasone sodium phosphate : 0,09 mg/ml	90		3174
PP		1,33 mg/ml	23°C		Neostigmine methylsulfate : 0.167 mg/ml	24		815
PP		1,33 mg/ml	23°C		Naloxone hydrochloride : 0,133 mg/ml	24		815

		1,33 mg/ml	23°C		Midazolam hydrochloride : 1,66 mg/ml	24		815
		1,33 mg/ml	23°C		Alfentanil hydrochloride : 167 µg/ml	24		815
		1,33 mg/ml	23°C		Atropine sulfate : 0,133 mg/ml	24		815
		1,33 mg/ml	23°C		Morphine sulfate : 2,67 mg/ml	24		815
		1,33 mg/ml	23°C		Pethidine hydrochloride : 8,33 mg/ml	24		815
		1 mg/ml	23°C		Propofol : 1 & 5 mg/ml	24		815
		1 mg/ml	23°C		Glycopyrronium bromide : 0,1 mg/ml	24		815
		1,33 mg/ml	4°C		Naloxone hydrochloride : 0,133 mg/ml	24		815
		1,33 mg/ml	4°C		Midazolam hydrochloride : 1,66 mg/ml	24		815
		1,33 mg/ml	4°C		Alfentanil hydrochloride : 167 µg/ml	24		815
		1,33 mg/ml	4°C		Atropine sulfate : 0,133 mg/ml	24		815
		1,33 mg/ml	4°C		Morphine sulfate : 2,67 mg/ml	24		815
		1,33 mg/ml	4°C		Pethidine hydrochloride : 8,33 mg/ml	24		815
		1 mg/ml	4°C		Glycopyrronium bromide : 0,1 mg/ml	24		815
		1,33 mg/ml	4°C		Neostigmine methylsulfate : 0.167 mg/ml	24		815
		0,16 mg/ml	20°C-25°C		Methylprednisolone sodium succinate : 2,4 mg/ml	24		2012
		0,08 mg/ml	23-27°C		Dexamethasone sodium phosphate : 0,1 mg/ml	48		3981
		0,08 mg/ml	23-27°C		Dexamethasone sodium phosphate : 0,2 mg/ml	48		3981
		0,16 mg/ml	4°C		Methylprednisolone sodium succinate : 2,4 mg/ml	48		2012
		0,08 mg/ml	2-8°C		Dexamethasone sodium phosphate : 0.1 mg/ml	30		3925
		0,074 mg/ml	2-8°C		Alizapride hydrochloride : 0,926 mg/ml	56		4479
		0,08 mg/ml	25°C		Tramadol hydrochloride : 10 mg/ml	14		4116
		0,08 mg/ml	4°C		Tramadol hydrochloride : 10 mg/ml	14		4116
		2 mg/ml	25°C		Paracetamol : 10 mg/ml	4		3571
		1 mg/ml	23°C		Droperidol : 1,25 mg/ml	8		815
		1,33 mg/ml	23°C		Fentanyl citrate : 16,7 µg/ml	24		815
		1 mg/ml	23°C		Metoclopramide hydrochloride : 2,5 mg/ml	24		815
		1,33 mg/ml	4°C		Fentanyl citrate : 16,7 µg/ml	24		815
		1 mg/ml	4°C		Metoclopramide hydrochloride : 2,5 mg/ml	24		815
		0,32 mg/ml	24°C		Fentanyl citrate : 16 µg/ml Oxycodone hydrochloride : 0,4 mg/ml Nefopam : 0,8 mg/ml	4		4666
		0,32 mg/ml	24°C		Fentanyl citrate : 16 µg/ml Hydromorphone hydrochloride : 0,08 mg/ml Nefopam : 0,8 mg/ml	4		4666



Facteur influençant la stabilité

				1415
				150 1396 3574
	PH >7			969 979



Compatibilités

		Ondansetron hydrochloride : 1 mg/ml Aciclovir sodium : 7 mg/ml	334
		Ondansetron hydrochloride Aciclovir sodium	3595
		Ondansetron hydrochloride : 0.7 mg/ml Aldesleukin : 0.0338 MUI/ml	36
		Ondansetron hydrochloride : 1.33 mg/ml Alfentanil hydrochloride : 167 µg/ml	815
		Ondansetron hydrochloride : 0.07 mg/ml Alizapride hydrochloride : 0.92 mg/ml	4479
		Ondansetron hydrochloride : 1 mg/ml Allopurinol sodium : 3 mg/ml	307
		Ondansetron hydrochloride : 1 mg/ml Amifostine : 10 mg/ml	3
		Ondansetron hydrochloride : 1 mg/ml Amikacin sulfate : 5 mg/ml	334
		Ondansetron hydrochloride : 1 mg/ml Aminophylline : 2.5 mg/ml	334
		Ondansetron hydrochloride : 2 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml	3824
		Ondansetron hydrochloride : 1 mg/ml Amphotericin B : 0.6 mg/ml	334
		Ondansetron hydrochloride : 1 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml	921
		Ondansetron hydrochloride : 1 mg/ml Ampicillin sodium : 20 mg/ml	334
		Ondansetron hydrochloride : 1 mg/ml Ampicillin sodium - sulbactam sodium : 20/10 mg/ml	334
		Ondansetron hydrochloride : 1 mg/ml Amsacrine : 1 mg/ml	334
		Ondansetron hydrochloride : 1.33 mg/ml Atropine sulfate : 0.133 mg/ml	815
		Ondansetron hydrochloride : 2 mg/ml Azithromycine : 2 mg/ml	1800

		Ondansetron hydrochloride : 1 mg/ml Aztreonam : 40 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Aztreonam : 40 mg/ml		99
		Ondansetron hydrochloride : 1 mg/ml Bleomycin sulfate : 1 mg/ml		334
		Ondansetron hydrochloride : 0.2 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml		3976
		Ondansetron hydrochloride : 2 mg/ml Caffeine : 10 mg/ml		3964
		Ondansetron hydrochloride : 1 mg/ml Carboplatin : 5 mg/ml		334
		Ondansetron hydrochloride : 0,016 >> 0,16 mg/ml Carboplatin : 0,18 >> 9,9 mg/ml		3574
		Ondansetron hydrochloride : 1 mg/ml Carmustine : 1.5 mg/ml		334
		Ondansetron hydrochloride : 2 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Ondansetron hydrochloride : 1 mg/ml Cefazolin sodium : 20 mg/ml		334
		Ondansetron hydrochloride : 0,16 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL	 	4528
		Ondansetron hydrochloride : 2 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Ondansetron hydrochloride : 1 mg/ml Cefoperazone sodium : 40 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Ceforanide : 20 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Cefotaxime sodium : 20 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Cefoxitin sodium : 20 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Ondansetron hydrochloride : 1 mg/ml Ceftaroline fosamil : 2,22 mg/ml	 	3249
		Ondansetron hydrochloride : 1 mg/ml Ceftazidime : 40 mg/ml		334
		Ondansetron hydrochloride : 0,016 >> 0,16 mg/ml Ceftazidime : 200 mg/ml		3574
		Ondansetron hydrochloride : 1 mg/ml Ceftizoxime sodium : 20 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	 	2269
		Ondansetron hydrochloride Ceftobiprole medocaril sodium		4650
		Ondansetron hydrochloride : 1 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Ondansetron hydrochloride : 0.16 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml	 	3828
		Ondansetron hydrochloride : 1 mg/ml Cefuroxime sodium : 30 mg/ml		334

	Ondansetron hydrochloride : 1 mg/ml Chlormethine hydrochloride : 1 mg/ml		334
	Ondansetron hydrochloride : 1 mg/ml Chlorpromazine hydrochloride : 2 mg/ml		334
	Ondansetron hydrochloride : 1 mg/ml Cimetidine hydrochloride : 12 mg/ml		334
	Ondansetron hydrochloride : 1 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
	Ondansetron hydrochloride : 1 mg/ml Cisplatin : 1 mg/ml		334
	Ondansetron hydrochloride : 0,48 mg/ml Cisplatin : 0,2 mg/ml		53
	Ondansetron hydrochloride : 1,091 mg/ml Cisplatin : 0,455 mg/ml		53
	Ondansetron hydrochloride : 0,016 >> 0,16 mg/ml Cisplatin : < 0,48 mg/ml		3574
	Ondansetron hydrochloride : 1 mg/ml Cladribine : 0.5 mg/ml		1496
	Ondansetron hydrochloride : 1 mg/ml Cladribine : 0.015 mg/ml		1496
	Ondansetron hydrochloride : 1 mg/ml Clindamycin phosphate : 10 mg/ml		334
	Ondansetron hydrochloride : 2 mg/ml Cloxacillin sodium : 100 mg/ml		3012
	Ondansetron hydrochloride : 0,4 mg/ml Cyclophosphamide : 2 mg/ml		50
	Ondansetron hydrochloride : 0,05 mg/ml Cyclophosphamide : 0,3 mg/ml		50
	Ondansetron hydrochloride : 0,016 >> 0,16 mg/ml Cyclophosphamide : 20 mg/ml		3574
	Ondansetron hydrochloride : 1 mg/ml Cyclophosphamide : 10 mg/ml		334
	Ondansetron hydrochloride : 1 mg/ml Cytarabine : 50 mg/ml		334
	Ondansetron hydrochloride : 0,03 mg/ml Cytarabine : 40 mg/ml		184
	Ondansetron hydrochloride : 0,3 mg/ml Cytarabine : 40 mg/ml		184
	Ondansetron hydrochloride : 0,3 mg/ml Cytarabine : 0,2 mg/ml		184
	Ondansetron hydrochloride : 0,03 mg/ml Cytarabine : 0,2 mg/ml		184
	Ondansetron hydrochloride : 0,03 mg/ml Dacarbazine : 1 mg/ml		184
	Ondansetron hydrochloride : 0,3 mg/ml Dacarbazine : 1 mg/ml		184
	Ondansetron hydrochloride : 0,3 mg/ml Dacarbazine : 3 mg/ml		184
	Ondansetron hydrochloride : 0,03 mg/ml Dacarbazine : 3 mg/ml		184
	Ondansetron hydrochloride : 1 mg/ml Dacarbazine : 4 mg/ml		334

	Ondansetron hydrochloride : 1 mg/ml Dactinomycin : 10 µg/ml		334
	Ondansetron hydrochloride : 1 mg/ml Daunorubicin hydrochloride : 2 mg/ml		334
	Ondansetron hydrochloride : 0.16 mg/ml Defibrotide : 8 mg/ml		3728
	Ondansetron hydrochloride : 0,14 >> 0,76 mg/ml Dexamethasone sodium phosphate : 0,22 >> 0,43 mg/ml		23
	Ondansetron hydrochloride : 0.08 mg/ml Dexamethasone sodium phosphate : 0.1 & 0.2 mg/ml		3981
	Ondansetron hydrochloride : 0.08 mg/ml Dexamethasone sodium phosphate : 0.1 mg/ml		3925
	Ondansetron hydrochloride : 0.16 mg/ml Dexamethasone sodium phosphate : 0.16 & 0.4 mg/ml		2841
	Ondansetron hydrochloride : 1 mg/ml Dexamethasone sodium phosphate : 1 mg/ml		334
	Ondansetron hydrochloride : 0,08 mg/ml Dexamethasone sodium phosphate : 0,1 mg/ml		3174
	Ondansetron hydrochloride : 0.1 >> 0.64 mg/ml Dexamethasone sodium phosphate : 0.2 & 0.4 mg/ml		30
	Ondansetron hydrochloride : 0,048 & 0,16 mg/ml Dexamethasone sodium phosphate : 0,02 >> 0,4 mg/ml		992
	Ondansetron hydrochloride : 0,14 & 0,45 mg/ml Dexamethasone sodium phosphate : 0,28 & 0,34 mg/ml		25
	Ondansetron hydrochloride : 1 mg/ml Dexmedetomidine : 4 µg/ml		1712
	Ondansetron hydrochloride : 1 mg/ml Diphenhydramine hydrochloride : 2 mg/ml		334
	Ondansetron hydrochloride : 1 mg/ml Docetaxel : 0.9 mg/ml		1754
	Ondansetron hydrochloride : 0.32 mg/ml Dopamine hydrochloride : 0.8 mg/ml		132
	Ondansetron hydrochloride : 1 mg/ml Doripenem : 5 mg/ml		2262
	Ondansetron hydrochloride : 0,3 mg/ml Doxorubicin hydrochloride : 0,1 mg/ml		184
	Ondansetron hydrochloride : 0,03 mg/ml Doxorubicin hydrochloride : 0,1 mg/ml		184
	Ondansetron hydrochloride : 0,016 >> 0,16 mg/ml Doxorubicin hydrochloride : 2 mg/ml		3574
	Ondansetron hydrochloride : 0,03 mg/ml Doxorubicin hydrochloride : 2 mg/ml		184
	Ondansetron hydrochloride : 1 mg/ml Doxorubicin hydrochloride : 2 mg/ml		334
	Ondansetron hydrochloride : 0,3 mg/ml Doxorubicin hydrochloride : 2 mg/ml		184
	Ondansetron hydrochloride : 1 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
	Ondansetron hydrochloride : 1 mg/ml Doxycycline hyclate : 1 mg/ml		334
	Ondansetron hydrochloride : 1 mg/ml Droperidol : 0.4 mg/ml		334







		Ondansetron hydrochloride : 1 mg/ml Droperidol : 1.25 mg/ml		815
		Ondansetron hydrochloride : 0,03 mg/ml Etoposide : 0,4 mg/ml		184
		Ondansetron hydrochloride : 0,03 mg/ml Etoposide : 0,1 mg/ml		184
		Ondansetron hydrochloride : 0,3 mg/ml Etoposide : 0,1 mg/ml		184
		Ondansetron hydrochloride : 1 mg/ml Etoposide : 0.4 mg/ml		334
		Ondansetron hydrochloride : 0,016 >> 0,16 mg/ml Etoposide : 0,14 >> 0,25 mg/ml		3574
		Ondansetron hydrochloride : 0,3 mg/ml Etoposide : 0,4 mg/ml		184
		Ondansetron hydrochloride : 1 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Ondansetron hydrochloride : 1 mg/ml Famotidine : 2 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Ondansetron hydrochloride : 1.33 mg/ml Fentanyl citrate : 16.7 µg/ml		815
		Ondansetron hydrochloride : 1 mg/ml Filgrastim : 30 µg/ml		244
		Ondansetron hydrochloride : 1 mg/ml Floxadine : 3 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Fluconazole : 2 mg/ml		334
		Ondansetron hydrochloride : 0.5 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Ondansetron hydrochloride : 0,016 >> 0,16 mg/ml Fluorouracil : < 0,8 mg/ml		3574
		Ondansetron hydrochloride : 0,07 mg/ml Fosaprepitant dimeglumine : 1 mg/ml		3459
		Ondansetron hydrochloride : 0.16 mg/ml Fosfomycin : 30 mg/ml		4055
		Ondansetron hydrochloride : 2 mg/ml		3948
		Ondansetron hydrochloride : 1 mg/ml Fluorouracil : 16 mg/ml		334
		Ondansetron hydrochloride Fluorouracil		3474
		Ondansetron hydrochloride : 0,016 >> 0,16 mg/ml Fluorouracil : > 0,8 mg/ml		3574
		Ondansetron hydrochloride : 1 mg/ml Furosemide : 3 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Gentamicin sulfate : 5 mg/ml		334
		Ondansetron hydrochloride : 0.064 mg/ml Haloperidol lactate : 0.02 >> 0.08 mg/ml		4036
		Ondansetron hydrochloride : 1.6 mg/ml Heparin sodium : 200 UI/ml		1699
		Ondansetron hydrochloride : 1 mg/ml		301

		Ondansetron hydrochloride : 0,3 mg/ml Gallium nitrate : 1 mg/ml		91
		Ondansetron hydrochloride : 1 mg/ml Glycopyrronium bromide : 0.1 mg/ml		815
		Ondansetron hydrochloride : 0.25 & 0.4 mg/ml Haloperidol lactate : 0.15 & 0.3 mg/ml		4082
		Ondansetron hydrochloride : 1 mg/ml Heparin sodium : 40 UI/ml		334
		Ondansetron hydrochloride : 2 mg/ml		150
		Ondansetron hydrochloride : 1 mg/ml Haloperidol lactate : 0.2 mg/ml		334
		Ondansetron hydrochloride : 0.1 mg/ml		1396
		Ondansetron hydrochloride		3574
		Ondansetron hydrochloride : 1 mg/ml Ganciclovir sodium : 20 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Ondansetron hydrochloride : 0.032 mg/ml Haloperidol lactate : 0.02 >> 0.08 mg/ml		4036
		Ondansetron hydrochloride : 1 mg/ml Hetastarch : 60 mg/ml		1721
		Ondansetron hydrochloride : 1 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Hydroxyzine dihydrochloride : 4 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Imipenem - cilastatin sodium : 5 mg/ml		334
		Ondansetron hydrochloride : 0.016 & 0.021 mg/ml		1868
		Ondansetron hydrochloride : 0,08 mg/ml Lornoxicam : 0,4 mg/ml		4429
		Ondansetron hydrochloride : 2 mg/ml		3948
		Ondansetron hydrochloride : 1 mg/ml Ifosfamide : 25 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Magnesium sulfate : 100 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Mannitol : 150 mg/ml		334
		Ondansetron hydrochloride : 0.2 mg/ml		3967
		Ondansetron hydrochloride : 0,1 & 1 mg/ml Hydromorphone hydrochloride : 0,5 mg/ml		6
		Ondansetron hydrochloride : 1 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Ondansetron hydrochloride : 0.16 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Ondansetron hydrochloride : 2 mg/ml Ketamine hydrochloride : 50 mg/ml		4389

		Ondansetron hydrochloride : 2 mg/ml Meropenem : 50 mg/ml		4319
		Ondansetron hydrochloride : 0.03 & 0.3 mg/ml		52
		Ondansetron hydrochloride : 1 mg/ml		1415
		Ondansetron hydrochloride : 1 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Ondansetron hydrochloride : 1 mg/ml Linezolid : 2 mg/ml		1925
		Ondansetron hydrochloride : 1 mg/ml Lorazepam : 0.1 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Melphalan : 0.1 mg/ml		169
		Ondansetron hydrochloride : 1 mg/ml Meropenem : 1 mg/ml		266
		Ondansetron hydrochloride : 2 mg/ml		4507
		Ondansetron hydrochloride : 1 mg/ml Meropenem : 20 & 50 mg/ml		266
		Ondansetron hydrochloride : 2 mg/ml Methotrexate sodium : 30 mg/ml		150
		Ondansetron hydrochloride : 0,03 mg/ml Methotrexate sodium : 6 mg/ml		184
		Ondansetron hydrochloride : 1 mg/ml Methylprednisolone sodium succinate : 5 mg/ml		334
		Ondansetron hydrochloride : 0,16 mg/ml Methylprednisolone sodium succinate : 2,4 mg/ml		2012
		Ondansetron hydrochloride : 1 mg/ml Metoclopramide hydrochloride : 2.5 mg/ml		815
		Ondansetron hydrochloride : 1 mg/ml Micafungin : 1.5 mg/ml		2108
		Ondansetron hydrochloride : 1.33 mg/ml Midazolam hydrochloride : 1.66 mg/ml		815
		Ondansetron hydrochloride : 0,02 mg/ml		4776
		Ondansetron hydrochloride : 1 mg/ml Mesna : 10 mg/ml		334
		Ondansetron hydrochloride : 0,3 mg/ml Methotrexate sodium : 0,5 mg/ml		184
		Ondansetron hydrochloride : 0,16 mg/ml Methylprednisolone sodium succinate : 2,4 mg/ml		2012
		Ondansetron hydrochloride : 0,0256 mg/ml		4579
		Ondansetron hydrochloride : 0,3 mg/ml Methotrexate sodium : 6 mg/ml		184
		Ondansetron hydrochloride : 1 mg/ml Methotrexate sodium : 15 mg/ml		334
		Ondansetron hydrochloride : 0,03 mg/ml Methotrexate sodium : 0,5 mg/ml		184
		Ondansetron hydrochloride : 0,16 mg/ml Methylprednisolone acetate : 2,4 mg/ml		2261
		Ondansetron hydrochloride : 1 mg/ml Metoclopramide hydrochloride : 5 mg/ml		334

		Ondansetron hydrochloride : 1 mg/ml Mitomycin : 0.5 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Mitoxantrone dihydrochloride : 0.5 mg/ml		334
		Ondansetron hydrochloride : 1.33 mg/ml Morphine sulfate : 2.67 mg/ml		815
		Ondansetron hydrochloride : 0,1 & 1 mg/ml Morphine sulfate : 1 mg/ml		6
		Ondansetron hydrochloride : 1 mg/ml Morphine sulfate : 1 mg/ml		334
		Ondansetron hydrochloride : 1.33 mg/ml Naloxone hydrochloride : 0.133 mg/ml		815
		Ondansetron hydrochloride : 2 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Ondansetron hydrochloride : 1.33 mg/ml Neostigmine methylsulfate : 0.167 mg/ml		815
		Ondansetron hydrochloride : 1 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Ondansetron hydrochloride : 0.5 mg/ml Paclitaxel : 1.2 mg/ml		248
		Ondansetron hydrochloride : 0.03 & 0.3 mg/ml Paclitaxel : 0.3 & 1.2 mg/ml		47
		Ondansetron hydrochloride : 2 mg/ml Paracetamol : 10 mg/ml		4742
		Ondansetron hydrochloride : 2 mg/ml Paracetamol : 10 mg/ml		3571
		Ondansetron hydrochloride Parecoxib sodium		2202
		Ondansetron hydrochloride : 1 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Ondansetron hydrochloride : 1 mg/ml Pentostatin : 0.4 mg/ml		334
		Ondansetron hydrochloride : 1.33 mg/ml Pethidine hydrochloride : 8.33 mg/ml		815
		Ondansetron hydrochloride : 1 mg/ml Pethidine hydrochloride : 4 mg/ml		334
		Ondansetron hydrochloride : 0.1 & 1 mg/ml Pethidine hydrochloride : 4 mg/ml		332
		Ondansetron hydrochloride : 0,5 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Ondansetron hydrochloride : 1 mg/ml Piperacillin sodium : 40 mg/ml		334
		Ondansetron hydrochloride : 0,015 >> 0,15 mg/ml Piperacillin sodium / tazobactam : 20/2,5 & 40/5 mg/ml		16
		Ondansetron hydrochloride : 0.1 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Ondansetron hydrochloride : 0.16 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Ondansetron hydrochloride : 0,48 mg/ml Posaconazole : 1,2 mg/ml		4521
		Ondansetron hydrochloride : 0,14 mg/ml Posaconazole : 1,2 mg/ml		4521

		Ondansetron hydrochloride : 1 mg/ml Potassium chloride : 100 mEq/l		334
		Ondansetron hydrochloride : 1 mg/ml Prochlorperazine edysilate : 0.5 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Promethazine hydrochloride : 2 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Propofol : 1 & 5 mg/ml		815
		Ondansetron hydrochloride : 0,03 >> 0,3 mg/ml Ranitidine hydrochloride : 0,5 & 2 mg/ml		18
		Ondansetron hydrochloride : 1 mg/ml Ranitidine hydrochloride : 2 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Ondansetron hydrochloride : 0.5 mg/ml Sargramostim : 10 µg/ml		335
		Ondansetron hydrochloride : 2 mg/ml Sodium bicarbonate : 14 mg/ml		150
		Ondansetron hydrochloride Sodium bicarbonate		3574
		Ondansetron hydrochloride : 0.1 mg/ml Sodium bicarbonate : 8.4 mg/ml		1396
		Ondansetron hydrochloride : 1 mg/ml Streptozocin : 30 mg/ml		334
		Ondansetron hydrochloride Sugammadex		2328
		Ondansetron hydrochloride : 0,16 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Ondansetron hydrochloride : 0.16 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Ondansetron hydrochloride : 1 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Ondansetron hydrochloride : 1 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Ondansetron hydrochloride : 1 mg/ml Teniposide : 0.1 mg/ml		905
		Ondansetron hydrochloride : 1 mg/ml Teniposide : 0.1 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Thiotepa : 1 mg/ml		249
		Ondansetron hydrochloride : 1 mg/ml Ticarcillin / clavulanic acid : 30/1 mg/ml		334
		Ondansetron hydrochloride : 0.48 mg/ml Topotecan : 0.056 mg/ml		1026
		Ondansetron hydrochloride : 0.08 mg/ml Tramadol hydrochloride : 10 mg/ml		4116
		Ondansetron hydrochloride : 0,016 mg/ml Tramadol hydrochloride : 0,4 mg/ml		2002
		Ondansetron hydrochloride : 1 mg/ml Vancomycin hydrochloride : 10 mg/ml		334
		Ondansetron hydrochloride : 1 mg/ml Vinblastine sulfate : 0.12 mg/ml		334

	Ondansetron hydrochloride : 1 mg/ml Vincristine sulfate : 0.05 mg/ml		334
	Ondansetron hydrochloride : 1 mg/ml Vinorelbine tartrate : 1 mg/ml		84
	Ondansetron hydrochloride : 1 mg/ml Zidovudine : 4 mg/ml		334



Voie d'administration



Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
6	Revue	Trissel LA, Xu QA, Martinez JF, Fox JL. Compatibility and stability of ondansetron hydrochloride with morphine sulfate and with hydromorphone hydrochloride in 0.9% sodium chloride injection at 4, 22 and 32°C. Am J Hosp Pharm 1994 ; 51: 2138-2142.
16	Revue	Chung KC, Moon YSK, Chin A, Ulrich WU, Gill MA. Compatibility of ondansetron hydrochloride and piperacillin sodium-tazobactam sodium during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1554-1556.
18	Revue	Pompilio FM, Fox JL, Inagaki K, Burm JP, Jhee S, Gill MA. Stability of ranitidine hydrochloride with ondansetron hydrochloride or fluconazole during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 391-394.
23	Revue	Evrard B, Ceccato A, Gaspard O, Delattre L, Delporte JP. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in 0.9% sodium chloride and in 5% dextrose injection. Am J Health-Syst Pharm 1997 ; 54: 1065-1068.
25	Revue	McGuire TR, Narducci WA, Fox JL. Compatibility and stability of ondansetron hydrochloride, dexamethasone, and lorazepam in injectable solutions. Am J Hosp Pharm 1993 ; 50: 1410-1414.
26	Revue	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL. Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. Am J Health-Syst Pharm 1997 ; 54: 915-920.
30	Revue	Hagan RL, Mallett MS, Fox JL. Stability of ondansetron hydrochloride and dexamethasone sodium phosphate in infusion bags and syringes for 32 days. Am J Health-Syst Pharm 1996 ; 53: 1431-1435.
36	Revue	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.

47	Revue	Burm JP, Jhee SS, Chin A, Moon YSK. Stability of paclitaxel with ondansetron or ranitidine hydrochloride during simulated Y site administration. Am J Hosp Pharm 1994 ; 51: 1201-1204.
50	Revue	Fleming RA, Olsen DJ, Savage PD, Fox JL. Stability of ondansetron hydrochloride and cyclophosphamide in injectable solutions. Am J Health-Syst Pharm 1995 ; 52: 514-516.
52	Revue	Kirkham JC, Rutherford ET, Cumingham GN, Daneshmand KA, Falls AL. Stability of ondansetron hydrochloride in a total parenteral nutrient admixture. Am J Health-Syst Pharm 1995 ; 52: 1557-1558.
53	Revue	Henry DW, Marshall JL, Nazzar OD, Fox JL, Leff RD. Stability of cisplatin and ondansetron hydrochloride in admixtures for continuous infusion. Am J Health-Syst Pharm 1995 ; 52: 2570-2573.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
113	Revue	Jhee SS, Jeong EW, Chin A, Inagaki K, Fox JL, Gill MA. Stability of ondansetron hydrochloride stored in a disposable, elastomeric infusion device at 4°C. Am J Hosp Pharm 1993 ; 50: 1918-1920.
132	Revue	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
150	Revue	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
179	Revue	Stiles ML, Allen LV Jr, Fox JL. Stability of ondansetron hydrochloride in portable infusion-pump reservoirs. Am J Hosp Pharm 1992 ; 49: 1471-1473.
183	Revue	Bosso JA, Prince RA, Fox JL. Stability of ondansetron hydrochloride in injectable solutions at -20, 5, and 25°C. Am J Hosp Pharm 1992 ; 49: 2223-2225.
184	Revue	Stewart JT, Warren FW, King DT, Fox JL. Stability of ondansetron hydrochloride and five antineoplastic medications. Am J Health-Syst Pharm 1996 ; 53: 1297-1300.

244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
332	Revue	Xu QA, Trissel LA, Fox JL. Compatibility of ondansetron hydrochloride with meperidine hydrochloride for combined administration. Ann Pharmacotherapy 1995 ; 29: 1106-1109.
333	Revue	Graham CL, Dukes GE, Kao CF, Bertch JM, Hak LJ. Stability of ondansetron in large-volume parenteral solutions. Ann Pharmacotherapy 1992 ; 26: 768-771.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
815	Revue	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
915	Revue	Casto DT. Stability of ondansetron stored in polypropylene syringes. Ann Pharmacotherapy 1994 ; 28: 712-714.

917	Revue	Blaise N, Vigneron J, Perrin A, Noirez V, Hoffman MA, Hoffman M. Stability of refrigerated and frozen solutions of ondansetron hydrochloride. EJHP 1994 ; 4: 12-13.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
969	Revue	Jarosinski PF, Hirschfeld S. Precipitation of ondansetron in alkaline solutions. N Engl J Med 1991 ; 325: 1315-1316.
979	Revue	D'Arcy PF. In vitro compatibility of granisetron with selected alkaline drugs. Int Pharm J 1995 ; 9: 57.
992	Revue	Beijnen JH, Koks CHW. Visual compatibility of ondansetron and dexamethasone. Ann Pharmacotherapy 1991 ; 25: 869.
1026	Revue	Mayron D, Gennaro AR. Stability and compatibility of topotecan hydrochloride with selected drugs. Am J Health-Syst Pharm 1999 ; 56: 875-881.
1396	Revue	Hauser AR, Trissel LA, Martinez JF. Ondansetron compatible with sodium acetate. J Clin Oncol 1993 ; 11: 197.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1699	Revue	Plaas S, Heck C, Kubrich M. Mischbarkeit von serotonin-antagonisten mit dexamethason und heparin. Krankenhauspharmazie 2000 ; 21: 107-109.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.

1800	Revue	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1868	Revue	Husson E, Crauste-Manciet S, Hadj-Salah E, Segier JC, Broissard D. Stabilité galénique de mélanges commercialisés de nutrition parentérale en présence de médicaments: médicaments dans le mélange. Nutr Clin Metab 2003 ; 17: 8-14.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2002	Revue	Abanmy NO, Zaghoul IY, Radwan MA. Compatibility of tramadol hydrochloride injection with selected drugs and solutions. Am J Health-Syst Pharm 2005 ; 62: 1299-1302.
2012	Revue	Bougouin C, Thelcide C, Crespin-Maillard F, Maillard C, Kinowski JM, Favier M. Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers. Am J Health-Syst Pharm 2005 ; 62: 2001-2005.
2108	Revue	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2202	Revue	Acin Lazaro MP, bono Arino C, martinez Bazan R, manzanas Marin I, Faci Bouthelier A, Velamazán Bloconá MJ, Facorro Gaspar E, Estabilidad de parecoxib en dilución con otros fármacos y administrado en perfusión continua IV para el control del dolor postoperatorio. Investig Clin Farm 2005 ; 2, 4: 195-203.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2261	Revue	Fernandez C, Pelloquin A, Berthoume M, Bellanger A, Farinotti R. Stabilité et compatibilité de l'association ondansétron-méthylprednisolone en solution. Can J Hosp Pharm 2008 ; 61, 3: 191-195.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2328	Laboratoire	Sugammadex (Bridion®) – Résumé des caractéristiques du produits Organon 2009
2841	Revue	Gonzalves Navaro M, Carril Aviles M, Borrás Almenar C, Romero Crespo I, Jimenez Torres NV. Estudio de estabilidad de la mezcla ondansetron-dexametasona en cloruro sodico 0,9%. Atencion Pharmaceutica 2009 ; 11, 3: 161-166.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.

3174	Revue	Rolin C, Hecq JD, Vanbeckbergen DF, Jamart J, Galanti LM. Stability of Ondansetron and Dexamethasone Infusion upon Refrigeration. Ann Pharmacotherapy 2011 ; 45: 130-131.
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3459	Revue	Sun S, Schaller J, Placek J, Duersch B. Compatibility of intravenous fosaprepitant with intravenous 5-HT3 antagonists and corticosteroids. Cancer Chemother Pharmacol 2013 ; 72: 509-513.
3474	Laboratoire	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3574	Laboratoire	Ondansetron - Résumé des caractéristiques du produit Accord Healthcare France SAS 2013
3595	Laboratoire	Aciclovir - Summary of Product Characteristics Hospira 2009
3728	Revue	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3925	Revue	Simar J, Godet M, Hecq J.-D, Closset M, Gillet P, Langhendries C, Bihin B, Jamart J, Galanti L. Long-term stability of dexamethasone and alizapride or ondansetron in sodium chloride 0.9% polyolefin bag at 5±3 C. Ann Pharm Fr 2016 ; 75, 1 : 30-39.
3948	Revue	Bouchoud L, Fonzo-Christe C, Klingmüller M, Bonnabry P. Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416-424.


3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3967	Revue	Staven V, Herra I, Wang S, Grönlie I, Tho I. Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents. J Pharm Pharmacol 2017 ;69,7:448-462
3976	Revue	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3981	Revue	He G, Zeng F, Lei K, Xia S, Deng L, Zhang C, Liu D. Compatibility of dexamethasone sodium phosphate with 5-HT ₃ receptor antagonists in infusion solutions: a comprehensive study EJHP 2017 ;24:162-166
4036	Revue	Estan-Cerezo G, Matoses-Chirivella C, Soriano-Iriga L, Murcia-Lopez A.C, Rodriguez-Lucena F.J, Navarro-Ruiz A. Stability and compatibility of ondansetron with haloperidol in parenteral admixtures. EJHP 2017 ;25,4: 200-203.
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4082	Revue	Espinosa-Bosch M, Sanchez-Rojas F, Bosche-Ojeda C. Stability of mixtures of ondansetron and haloperidol stored in infusers at different temperatures. EJHP 2018 ; 25, e2
4116	Revue	Chen F, Zhu J, Li B, Yuan F, Wang K. Stability of tramadol with three 5-HT ₃ receptor antagonists in polyolefin bags for patient-controlled delivery systems. Drug Design Dev Ther 2016 ;10:1869-1875
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Revue	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévamisentan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4429	Revue	Fang B-X, Li P, Shi X-Y, Chen F.C, Wang L.H. Incompatibilities of lornoxicam with 4 antiemetic medications in polyolefin bags during simulated intravenous administration. Medicine 2016 ; 95:25(e3824)
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4479	Revue	Closset M, Goderniaux N, Colsoul M-L, Soumoy L, Bihin B, Jamart J, Odou P, Hecq J-D, galanti L. Long term stability of an admixture of alizapride and ondansetron in 0.9% sodium chloride solution polyolefin bags stored at 5 +/- 3°C. J Oncol Pharm Practice 2020 ;27,6:1328-1332
4507	Revue	Ross E, Salinas A, Petty K, Her C, Carpenter J. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health-Syst Pharm 2020 ;77,23:1980-1985

4521	Revue	Polo C, D'Huart E, Lesperlette G, Vigneron J, Meyer F, Demoré B. Compatibility of injectable posaconazole with drugs commonly used in a hematology care unit. Pharmaceutical Technology in Hospital Pharmacy 2020
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4579	Revue	Tomczak S, Radwan V, Jelinska A, Stawny M. Application of the HPLC Method in Parenteral Nutrition Assessment: Stability Studies of Ondansetron Processes 2021 , 9, 453.
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4666	Revue	Lee C.H, Kim A.R, Lee M.K, Oh J.S, Lee D.K, Choi S.S. Intravenous patient-controlled analgesia: in vitro stability profiles of mixtures containing fentanyl, hydromorphone, oxycodone, nefopam, ondansetron, and ramosetron. J Anal Sci Tech 2020 ; 11: 32.
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4776	Revue	Tomczak S, Chmielewski, M, Szkudlarek J, Jeliinska A. Antiemetic Drugs Compatibility Evaluation with Paediatric Parenteral Nutrition Admixtures. Pharmaceutics 2023 ; 15: 2143.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Stabilis



Ondansetron hydrochloride



Stabilité des préparations

		3.2 mg Zofran®	Jus de pomme >> 100 ml	2-8°C		72			2445
		9.6 mg Zofran®	Jus de pomme >> 100 ml	2-8°C		72			2445
		3.2 mg Zofran®	Jus de pomme >> 100 ml	22-28°C		72			2445
		9.6 mg Zofran®	Jus de pomme >> 100 ml	22-28°C		72			2445
		120 mg ® = ?	SyrSpend SF PH4® >> 150 mL	2-8°C		90			3994
		120 mg ® = ?	SyrSpend SF PH4® >> 150 mL	20-25°C		90			3994
		8 mg Zofran®	Coca Cola® 26 ml	25-27C		1			2481
		8 mg Zofran®	Jus d'orange 116 ml	25-27C		1			2481
		8 mg Zofran®	Coca Cola® 116 ml	25-27C		1			2481
		8 mg Zofran®	Jus d'orange 26 ml	25-27C		1			2481
		80 mg Zofran®	OraPlus® 50 ml Sirop de cerise 50 ml	4°C		42			2517
		80 mg Zofran®	OraPlus® 50 ml Syrpalta® 50 ml	4°C		42			2517
		80 mg Zofran®	OraPlus® 50 ml Orasweet® 50 ml	4°C		42			2517
		80 mg Zofran®	OraPlus® 50 ml Orasweet SF® 50 ml	4°C		42			2517








































































Bibliographie

	Type	Source
2445	Revue	Yamreudeewong W, Danthi SN, Hill RA, Fox JL. Stability of ondansetron hydrochloride injection in various beverages Am J Health-Syst Pharm 1995 ; 52: 2011-2014.
2481	Revue	Graham CL, Dukes GE, Fox JL, Kao CF, Hak LJ. Stability of ondansetron hydrochloride injection in extemporaneously prepared oral solutions Am J Hosp Pharm 1993 ; 50: 106-108.
2517	Revue	Williams CL, Sanders PL, Laizure SC, Stevens RC, Fox JL, Hak LJ. Stability of ondansetron hydrochloride in syrups compounded from tablets Am J Hosp Pharm 1994 ; 51: 806-809.
3994	Revue	De Oliveira Ferreira A, Polonini H C, Loures da Silva S, Cerqueira de Melo V Augusto, de Andrade L, Fernandes Brand?o Marcos A. Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabalin, and Riboflavin in SyrSpend SF pH4 Oral Suspensions. Int J Pharm Compound 2017 ; 3: 255-263



Dictionnaire

 Antiémétique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Polyvinyl chlorure
 NaCl 0,9% ou glucose 5%	 Lumière
 Jour	 A l'abri de la lumière
 Heure	 Chlorure de sodium 0,9%
 Non précisée	 Aucun
 Seringue polypropylène	 Elastomère en polyisoprène
 Stabilité en mélange	 Solvant
 Molécule	 Verre
 Glucose 5%	 Polyéthylène
 Polypropylène	 Polyolefine
 Eau pour préparation injectable	 Non précisé
 Facteur influençant la stabilité	 Nutrition parentérale (mélange ternaire)
 Provoque	 Dégradation
 NaHCO ₃	 Précipitation
 Compatibilités	 Précipitation immédiate
 Incompatible	 Incompatibilité non précisée
 Compatible	 Turbidité immédiate
 Précipitation en 30 minutes	 RL Ringer lactate
 NaCl 0,9% + bactériostatique	 Précipitation en 24 heures
 Nutrition parentérale (mélange binaire)	 Précipitation en 1 heure
 Solvant spécifique	 Instabilité de l'émulsion immédiate
 Turbidité en 30 minutes	 Voie d'administration
 Intraveineuse	 Perfusion intraveineuse
 Perfusion continue	 Perfusion sous-cutanée

	Bibliographie		Solution buvable
	Stabilité des préparations		Origine
	Excipient		Flacon injectable
	Flacon plastique		Poudre
	Comprimés		Dictionnaire